U.S. Office REITs Stock News

Imperial Petroleum Inc. recently reported fourth-quarter 2025 results, with sales of US$51.14 million and net income of US$14.96 million, and also declared a US$0.546875 preferred dividend on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock for payment on March 30, 2026. While quarterly sales and earnings increased compared with the prior year’s quarter, full-year 2025 net income and earnings per share from continuing operations remained broadly in line with 2024 levels,...

Trupanion (NasdaqGM:TRUP) announced a new partnership with the Human Animal Bond Research Institute (HABRI). The collaboration focuses on research and advocacy that supports the human and animal connection, including pet owners, veterans, service animals, and special populations. The initiative aims to use data driven insights to inform programs and policies that affect pet and human welfare. For you as an investor, this adds another layer to Trupanion's core pet insurance business. The...

Matson announced the upcoming retirement of Executive Vice President and Chief Commercial Officer John Lauer and named Chris Scott as his successor. The company outlined additional leadership promotions connected to this transition. Matson also launched a new cargo security initiative with BNSF Railway and War-Lok, adding multiple layers of protection for international intermodal cargo. Matson (NYSE:MATX) is pairing major leadership changes with an operational shift in how it protects...

Gambling.com Group (GAMB) closed FY 2025 with Q4 revenue of US$46.2 million and a basic EPS loss of US$0.77, alongside a trailing twelve month basic EPS loss of US$0.93 on revenue of US$165.4 million. The company has seen quarterly revenue move from US$35.3 million and basic EPS of US$0.23 in Q4 2024 to US$46.2 million with a basic EPS loss of US$0.77 in Q4 2025, while trailing twelve month revenue shifted from US$127.2 million with basic EPS of US$0.85 in Q4 2024 to US$165.4 million with a...

Century Therapeutics (IPSC) just posted FY 2025 results that put revenue at US$109.2 million with basic EPS of US$0.51 for the latest half, against a trailing twelve month profile that still shows a loss, with EPS of US$0.11 and net income of US$9.6 million in the red on US$109.2 million of revenue. Over the past year, the company has reported revenue of US$1.6 million and EPS of US$0.82 in early 2024, then US$4.96 million with EPS of US$0.79 in the second half of 2024, and then the latest...

CareCloud (CCLD) has capped FY 2025 with fourth quarter revenue of US$34.4 million and basic EPS of US$0.04, alongside trailing 12 month revenue of US$120.5 million and basic EPS of US$0.10, marking a clean move away from the losses seen earlier in the period. The company has seen quarterly revenue step up from US$27.4 million in Q2 2025 to US$34.4 million in Q4 2025, while quarterly basic EPS has shifted from a loss of US$0.04 in Q1 2025 to positive readings in each subsequent quarter,...

Trinity Capital (NasdaqGS:TRIN) has recently committed growth capital to three MedTech companies: Monteris Medical, Emboline, and Neuros Medical. The financing supports commercialization of Monteris Medical's neurosurgical system, Emboline's heart procedure protection platform, and Neuros Medical's non opioid pain treatment device. These back to back commitments expand Trinity Capital's exposure to advanced medical technologies within its venture lending portfolio. Trinity Capital focuses...

Voyager Therapeutics, Inc. recently reported fourth-quarter 2025 results showing a net loss of US$27.43 million, improving from US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 million from US$65.00 million in 2024. Although Voyager reduced its quarterly loss per share, the much larger full-year loss highlights the cost intensity of advancing its neurological disease pipeline. We’ll now examine how Voyager’s improved quarterly loss but much larger...

Zurn Elkay Water Solutions (NYSE:ZWS) reported record annual performance with double digit core sales growth. The company highlighted improved operating margins over the year. Management announced a substantial increase in its dividend. The company also disclosed a significant share repurchase program. Zurn Elkay Water Solutions focuses on water management products and systems, an area that sits at the intersection of infrastructure, building construction, and resource efficiency. With...

Montauk Renewables (MNTK) closed out FY 2025 with Q4 revenue of US$43.4 million and basic EPS of US$0.02 on net income of US$2.5 million, setting the tone for a year where reported earnings and margins were under close watch. The company has seen quarterly revenue move from US$27.7 million and basic EPS of US$0.06 in Q4 2024 to a mix of losses and profits through 2025, including Q2 revenue of US$45.1 million with a loss of US$5.5 million and basic EPS of US$0.04, before landing on US$45.3...

Sleep Number (SNBR) has capped FY 2025 with fourth quarter revenue of US$347.4 million and a basic EPS loss of US$2.55, as net income excluding extra items came in at a loss of US$58.5 million. The company has seen quarterly revenue move from US$393.3 million in Q1 2025 to US$327.9 million in Q2, US$342.9 million in Q3 and US$347.4 million in Q4, alongside a widening basic EPS loss over the same stretch. For investors, that mix of steady sales levels and deeper losses keeps the focus firmly...

Q32 Bio (QTTB) has just posted its FY 2025 numbers, reporting fourth quarter revenue of US$53.7 million and basic EPS of US$4.60, alongside trailing 12 month basic EPS of US$2.42 and net income of US$29.8 million. The company’s quarterly revenue has moved from US$0 and a basic EPS loss of US$1.16 in Q4 2024 to US$53.7 million and US$4.60 in Q4 2025. Interim 2025 quarters showed no revenue and basic EPS losses between US$0.60 and US$0.90, so investors will likely focus on how durable these...

LifeMD (LFMD) is back in focus after its latest earnings, where the telehealth provider reported full year 2025 net income of US$14.35 million and issued fresh 2026 revenue guidance. See our latest analysis for LifeMD. LifeMD’s latest earnings and 2026 guidance have arrived after a sharp recent move, with a 7 day share price return of 31.17% and a 30 day share price return of 29.02% despite a 1 year total shareholder return decline of 30.48%. Short term momentum is building, while the longer...

Bumble (BMBL) has returned to investor attention after Q4 2025 earnings topped expectations, first quarter 2026 revenue guidance of US$209 million to US$213 million, and the announcement of new AI driven product and platform plans. See our latest analysis for Bumble. The Q4 surprise and AI rollout have triggered a sharp shift in sentiment, with a 34.2% 1-day share price return and 21.7% 7-day share price return contrasting with a 1-year total shareholder return of negative 20%. This suggests...

Resolute Holdings Management (RHLD) has put out a mixed set of FY 2025 numbers, with Q3 revenue at US$120.9 million and a small net loss of US$0.2 million, translating to basic EPS of US$0.03 loss per share. Over recent quarters the company has seen revenue move from US$103.9 million in Q1 FY 2025 to US$119.6 million in Q2 and US$120.9 million in Q3. EPS shifted from a US$0.39 loss to a US$0.07 loss and then to a US$0.03 loss, setting the backdrop for investors who are watching how much of...

Kansas City Life Insurance (KCLI) has wrapped up FY 2025 with fourth quarter revenue of US$120.4 million, basic EPS of US$0.23 and net income of US$2.3 million, alongside trailing 12 month revenue of US$485.5 million and a net loss of US$20.8 million, which translates to basic EPS of a US$2.14 loss. Over recent quarters the company has seen revenue move between US$118.98 million and US$125.15 million, while quarterly EPS has ranged from a US$2.90 loss to a US$0.33 profit. This sets up a story...

Inland Real Estate Income Trust (INRE) has posted its FY 2025 numbers with Q4 total revenue of US$38.7 million and a basic EPS loss of US$0.12, alongside funds from operations of US$36.3 million in the red. This gives investors a mixed read on operating performance and cash generation. Over the past year, total revenue has held in a tight band around US$150 million on a trailing twelve month basis while basic EPS for the same period came in at a loss of US$0.31, underscoring a sustained loss...

Sealed Air (NYSE:SEE) has announced its intention to redeem multiple senior notes, subject to the closing of a pending transaction. The planned redemptions would retire certain outstanding debt instruments once the transaction is completed. The company has outlined the expected redemption terms ahead of closing to give bondholders and shareholders clarity on next steps. For investors watching Sealed Air, the focus now is on how this conditional redemption plan fits with the company’s...

If you are wondering whether Amicus Therapeutics at around US$14.37 is attractively priced or already reflecting a lot of optimism, you are in the right place to focus on what the numbers are actually saying about value. The stock's return profile, with 0.3% over the last 7 days, 0.5% over 30 days, 0.7% year to date and 61.6% over 1 year, suggests the market has been reassessing the company over different time frames. Recent news around Amicus Therapeutics has continued to center on its role...

Centessa Pharmaceuticals recently reported past Phase II progress for its orexin agonist ORX750 in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, highlighting clinically meaningful effects alongside a favorable safety and tolerability profile. The company also outlined plans for registrational studies in rare hypersomnias, expanded its open-label extension to four weeks, and began preparing for regulatory engagement and commercial build-out, underscoring how central ORX750...

Conference spotlight and why AIRO is on more investor radars AIRO Group Holdings (AIRO) is set to present at the 2026 Cantor Global Technology & Industrial Growth Conference on March 11 in New York, giving investors a closer look at its aerospace and defense business. With Co Founder and Executive Chairman Chirinjeev Baboo Kathuria, Chief Executive Officer Joe Burns and Chief Financial Officer Mariya Pylypiv on stage, the session could offer more detail on AIRO’s drone, avionics, training and...

Valvoline (NYSE:VVV) has launched the Happy to Help Fund in partnership with Blue Grass Community Foundation to back mental and physical well-being projects for children and youth in Lexington. The company has named Jordan M. Denny as Chief Accounting Officer and Controller, marking a key update to its executive leadership team. For you as an investor, this pairs a fresh community initiative with a leadership change at a company best known for vehicle lubricants, services, and related...

Immunic (IMUX) is back on investors’ radar after proposing a reverse stock split ahead of an April 14 special shareholder meeting, while management prepares to speak at the Leerink Global Healthcare Conference on March 11. See our latest analysis for Immunic. Those recent corporate updates have come alongside sharp share price moves, with a 1 day share price return of 12.4% and a 30 day share price return of 103.08% contributing to a year to date share price return of 148.71%. However, the 5...

Vanda Pharmaceuticals recently received a decision from the U.S. FDA granting a rare formal evidentiary public hearing to review the agency’s proposed refusal to approve a supplemental new drug application for HETLIOZ (tasimelteon) as a treatment for jet lag disorder. This hearing, which follows Vanda’s earlier legal win requiring the FDA to more fully address its clinical evidence, highlights unusually high regulatory and scientific scrutiny around expanding HETLIOZ into a large, currently...